RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BARD1 Life Sciences Stock

BARD1 Life Sciences Equity 2024

BARD1 Life Sciences Equity

29.06 M AUD

Ticker

BD1.AX

ISIN

AU000000BD12

WKN

A2AL50

In 2024, BARD1 Life Sciences's equity was 29.06 M AUD, a 0% increase from the 0 AUD equity in the previous year.

BARD1 Life Sciences Aktienanalyse

What does BARD1 Life Sciences do?

BARD1 Life Sciences Ltd. is an Australian biotechnology company specializing in the development of diagnostics and therapeutics for cancer. The company was founded in 1999 and is headquartered in Sydney. BARD1 Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing BARD1 Life Sciences's Equity

BARD1 Life Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BARD1 Life Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BARD1 Life Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BARD1 Life Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BARD1 Life Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BARD1 Life Sciences stock

What is the equity of BARD1 Life Sciences this year?

BARD1 Life Sciences has equity of 29.06 M AUD this year.

What was the equity of BARD1 Life Sciences compared to the previous year?

The equity of BARD1 Life Sciences has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of BARD1 Life Sciences?

A high equity is advantageous for investors of BARD1 Life Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of BARD1 Life Sciences?

A low equity can be a risk for investors of BARD1 Life Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of BARD1 Life Sciences affect the company?

An increase in equity of BARD1 Life Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of BARD1 Life Sciences affect the company?

A reduction in equity of BARD1 Life Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of BARD1 Life Sciences?

Some factors that can affect the equity of BARD1 Life Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of BARD1 Life Sciences so important for investors?

The equity of BARD1 Life Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can BARD1 Life Sciences take to change the equity?

To change equity, BARD1 Life Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does BARD1 Life Sciences pay?

Over the past 12 months, BARD1 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BARD1 Life Sciences is expected to pay a dividend of 0 AUD.

What is the dividend yield of BARD1 Life Sciences?

The current dividend yield of BARD1 Life Sciences is .

When does BARD1 Life Sciences pay dividends?

BARD1 Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BARD1 Life Sciences?

BARD1 Life Sciences paid dividends every year for the past 0 years.

What is the dividend of BARD1 Life Sciences?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BARD1 Life Sciences located?

BARD1 Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BARD1 Life Sciences from 12/3/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

When did BARD1 Life Sciences pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of BARD1 Life Sciences in the year 2023?

In the year 2023, BARD1 Life Sciences distributed 0 AUD as dividends.

In which currency does BARD1 Life Sciences pay out the dividend?

The dividends of BARD1 Life Sciences are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BARD1 Life Sciences

Our stock analysis for BARD1 Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BARD1 Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.